[1] Hopkins A L,Groom C R.The druggable genome[J].Nat.Rev.Drug Disc.,2002,1(9):727-730. [2] Drews J.Drug discovery:a historical perspective[J].Science,2000,287(5460):1960-1964. [3] Torchilin V P,Lukyanov A N.Peptide and protein drug delivery to and into tumors:challenges and solutions[J].Drug Discov.Today,2003,8(6):259-266. [4] Engvall E.Enzyme immunoassay ELISA and EMIT[J].Methods Enzymol.,1980,70(A):419. [5] 李高.稳定同位系标记药物在临床药代动力学研究中的应用[J].中国临床药理学杂志,2000,16(1):58-62.Li G.The application of stable isotope labelled drugs in clinical pharmacokinetic study[J].Chin.J.Clin.Pharmacol.,2000,16(1):58-62. [6] Meager A.Biological assays for interferons[J].J.Immunol.Methods,2002,261(1):21-36. [7] 张琪,王广基.蛋白多肽类药物药代动力学分析方法研究进展[J].药物生物技术,2000,7(2):126-128.Zhang Q,Wang G J.The progress of the analysis method of protein polypeptide drug pharmacokinetics[J].Pharm.Biotechnol.,2000,7(2):126-128. [8] Woodnutt G,Berry V.Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of streptococcus pneumoniae[J].Antimicrob.Agents Ch.,1999,43(1):29. [9] Koopmans S J,Wee-Pals L V D,Lowik C,et al.Use of a rat model for the simultaneous assessment of pharmacokinetic and pharmacodynamic aspects of bisphosphonate treatment:Application to the study of intravenous 14C-labeled 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate[J].J.Bone Miner.Res.,2009,9(2):241-246. [10] Weiss H R.Measurement of cerebral capillary perfusion with a fluorescent label[J].Microvasc.Res.,1988,36(2):172-180. [11] Cabaniss S E.Synchronous fluorescence spectra of metal-fulvic acid complexes[J].Environ.Sci.Technol.,1992,26(6):1133-1139. [12] Patra D,Mishra A K.Recent developments in multi-component synchronous fluorescence scan analysis[J].TrAC-Trend.Anal.Chem.,2002,21(12):787-798. [13] Lorenz J,Gruenstein E.A simple,nonradioactive method for evaluating single-nephron filtration rate using FITC-inulin[J].Am.J.Physiol.-Renal Physiol.,1999,276(1):F172-F177. |